NDAOPHTHALMICOINTMENT
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEO-HYDELTRASOL is a fixed-dose ophthalmic ointment combining neomycin sulfate (antibiotic) and prednisolone sodium phosphate (corticosteroid) for topical eye treatment. This combination addresses bacterial infection and inflammation simultaneously in ocular conditions. The product targets patients requiring dual antimicrobial and anti-inflammatory therapy for external eye disease.
Pre-Launch
Pre-launch stage indicates active commercial team building for launch preparation, with growth potential dependent on market adoption and formulary positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEO-HYDELTRASOL offers entry into a pre-launch product cycle within Merck's established ophthalmic franchise, providing opportunity to shape launch strategy and establish market positioning from inception. Career growth depends on successful market introduction and ability to compete effectively against established combination therapies.
Brand ManagerProduct Manager
Worked on NEO-HYDELTRASOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.